Joint Annual Research Report 2004 - The Royal Marsden

Financial Facts and Figures
The principal sources of income and the expenditure
of our joint institution are summarised in the Facts
and Figures page (page 12). Full and detailed
statements of the financial accounts of The Institute
of Cancer Research (August 2003 to July 2004) and
The Royal Marsden NHS Foundation Trust (April 2004
to March 2005, to be published in September 2005)
are separately recorded in our respective Annual
Reports and Accounts. In the financial year ending on
31 March 2005, the Trust met its key financial objectives
and achieved a balanced budget. In the financial year
ending on 31 July 2004, The Institute achieved a
balanced budget on unrestricted funds after transfers.
Its expenditure on research grew by 10.7% from the
previous year, with increases in research expenditure
across a number of research Sections.
Overall, the combined
annual turnover of
our organisation was
£203.1 million, with
89% of this total being
devoted to research
activities and patient
care services.
Government funding for our joint research activities
contributes 42% of the total resources for research.
Our success rate in competing for research funding
from external sources continues to be outstanding,
at 75% of the value of all applications for peerreviewed
grants to medical charities and government
funding agencies. The Institute is particularly indebted
to its major funding partners – Cancer Research UK,
Breakthrough Breast Cancer, Leukaemia Research,
the Wellcome Trust, the Medical Research Council,
Department of Health, and many other medical
research sponsors.
New commercial partners collaborating in drug
development at The Institute and supporting clinical
trials at the Royal Marsden include: AstraZeneca,
Novartis, Vernalis Ltd, Astex Technology Ltd, Pfizer,
Antisoma and BTG.
Many organisations also contribute support by
providing funds for studentships at The Institute and
clinical fellowships at the hospital. The Royal Marsden
and The Institute are grateful to all the numerous
organisations and supporters who have made
investments in our research activities.
Fundraising
The Royal Marsden publicly launched its £30 million
appeal to finance a number of major projects to provide
a range of new facilities and leading edge equipment
which will enhance the hospital’s research capacity as
well as provide improved treatments for patients.
Generous gifts from an anonymous charitable
foundation, the Oak Foundation, the Garfield Weston
Foundation, John and Catherine Armitage, the PF
Charitable Trust, the Wolfson Foundation, the Arbib
Foundation, Martin Myers and a number of other trusts
and private individuals, brought the sum pledged to £24
million by the end of the year. The loyal support of the
hospital’s staff and patients, their families and friends
and the general public contributed some £2 million to
that total. Our thanks go to all the dedicated people
who have done so much to bring the appeal’s final
target in sight so speedily.
The Institute continues to receive significant support
from charitable trusts, companies and an increasing
number of individuals. Our Everyman Male Cancer